IPFA/PEI 14th Workshop on  
“Surveillance and Screening of Blood Borne Pathogens”

In collaboration with the Polish Institute of Hematology and Hemotherapy
In conjunction with the 23rd meeting of the National Network of Surveillance of Blood Borne Pathogens

Warsaw
15-16 May 2010

IPFA/PEI 17th Workshop on  
“Surveillance and Screening of Blood Borne Pathogens”

In collaboration with the Italian National Institute of Health
In conjunction with the 23rd meeting of the National Network of Surveillance of Blood Borne Pathogens

Zagreb
25-26 May 2010

IPFA/PEI 15th Workshop on  
“Surveillance and Screening of Blood Borne Pathogens”

11-12 May 2008
Vienna

IPFA/PEI 18th Workshop on  
“Surveillance and Screening of Blood Borne Pathogens”

In collaboration with the Irish Health Protection Surveillance Centre
24-25 May 2011
Dublin

IPFA/PEI 13th NAT Workshop on  
“Surveillance and Screening of Blood Borne Pathogens”

In collaboration with Swiss National Health Authority
In conjunction with the XIX meeting of the NAT Network
12-13 June 2006
Bern, Switzerland

IPFA/PEI 16th Workshop on  
“Surveillance and Screening of Blood Borne Pathogens”

In collaboration with the Belgian Scientific Institute of Public Health (IDH)
In conjunction with the 22nd meeting of the National Network of Surveillance of Blood Borne Pathogens
26-27 May 2009
Brussels, Belgium

IPFA/PEI 19th International Workshop on  
“Surveillance and Screening of Blood Borne Pathogens”

In collaboration with the Hungarian National Blood Transfusion Service
23-24 May 2012
Budapest, Hungary
EPFA & PEI 11th NAT Workshop

"Surveillance and Screening of Blood Borne Pathogens"

PARIS

May 15-16, 2004
Maison de la Chimie, Paris, France

- Review of 10 year global experience with HIV/HCV NAT (Busch)
- Potential for HBV-NAT in endemic & non-endemic areas (Yoshisawa, Assal)
- WNV epidemic and response to TT cases in the USA (Stramer)
- Variant B19 viruses (Blumel)
- vCJD screening – technologies and feasibility (Brown)
- Malaria and Chagas screening – deferrals, serology or NAT (Kitchen)
- Bacteria screening options (Montag-Lessing)
- Viral discovery and rapid response with new technologies
  - Metagenomic (Delwart)
  - Protein microarrays (Baas)
  - DNA chip technology (Herman)
- Developing world initiatives - GCBS; Safe Blood for Africa; Asia-Pacific
IPFA/PEI 12th NAT Workshop on
"Surveillance and Screening of Blood Borne Pathogens"
Co-sponsored by the U.S. Food and Drug Administration (FDA)

BETHESDA MD

26-27 May 2005
Natcher Facility, NIH Campus, Bethesda MD, USA
12th IPFA/PEI NAT Workshop (Bethesda, 2005)

• Future of Global Blood Safety (Dodd)

• NAT Implementation/Yield – Vox International Forum (Coste)

• Implementation of HBV-NAT: sensitivity, risk reduction (Hollinger, Roth, Chudy)

• Application of NAT for Parvovirus B19 and HAV (Allain, Yu, Kreil)

• Application of NAT to organ, tissue & cell donors (Greenwald, Strong, Niesters)

• Screening other pathogens: bacteria, CA-viruses, vCJD (Reesink, Roback, Asher)

• Advances in NAT automation: COBAS s201; Ultrio TIGRIS (Herman, Phelps)

• Global Session
  • HCV testing in developing world (Scheiblauer)
  • Rapid tests for blood screening in endemic areas (Lee)
  • Risky Blood in Caribbean and Latin America (Cruz)
IPFA/PEI 13th NAT Workshop on
“Surveillance and Screening of Blood Borne Pathogens”

In collaboration with Swissmedic
In conjunction with the XIX meeting of the SoGAT

12-13 June 2006
Allegro Kursaal, Bern, Switzerland
• Ethical considerations in blood safety policies (Sugarman)

• Regulatory harmonization vs diversity (Hewlett, Krusius, Nubling)

• Global Session – equity vs differential safety due to resource constraints
  • Eastern Europe (Brojer)
  • SE Asia (Liu)
  • South Africa (Crookes)

• HBV - NAT vs anti-HBV screening (Lelie, Gerlich, Niederhauser)

• Cell-associated and vector-borne viruses - NAT vs serology (Busch; Niedrig)

• Head-to-head comparisons of automated NAT systems (Margaritis; Assal)

• New technologies: micorarrays & nanotechnology (Hirschberg; Gehring)

• Repositories: rationale, approaches, ethics (Roth, Simmonds, Dodd, Sugarman)
IPFA/PEI 14th Workshop on
“Surveillance and Screening of Blood Borne Pathogens”

In collaboration with the Polish Institute of Haematology and Transfusion Medicine
In conjunction with the XX meeting of SoGAT

14-15 June 2007
Warsaw, Poland
14th IPFA/PEI NAT Workshop (Warsaw, 2007)

- HIV and HCV: basic science to blood safety (Weiss, Bartenschlager, Simmonds)

- HBV
  - OBI: molecular characterization & pathobiology (Allain, Raimonda)
  - HBV sero/molecular epidemiology in NE Europe (Cianciara)
  - Comparison of world-wide HBV assays (Nick)

- 4th generation HIV and HCV Ag/Ab assays (Hausmann)

- Does NAT make sense in developing/resource limited settings? (Brojer, Qiu)

- Screening strategies
  - Viral and host factors influencing transmission (Dodd)
  - Serology vs NAT: science and regulatory perspectives (Laperche, Minor)
  - Cost-effectiveness of NAT vs serology in different environments (van Hulst)
  - Screening vs PRT (Blumel)

- PRT
  - Toronto Consensus Conference on PRT (Osselaer)
  - Belgium and French experience with PRT (Osselaer and Cazenave)
IPFA/PEI 15th Workshop on
“Surveillance and Screening of Blood Borne Pathogens”

13-15 May 2008

The Imperial Riding School Vienna
A Renaissance Hotel
Austria
15th IPFA/PEI NAT Workshop (Vienna, 2008)

- HBV
  - Implications of genome variability (Bruss)
  - Animal (chimps and humanized mice) of infectivity (Yoshizawa)
  - Detection, infectivity and pathogenicity (Gerlich)
  - Occult HBV Infections (Allain)
  - HBV testing policies in European countries: NAT vs anti-HBC (van der Poel)

- Parvo B19
  - Genotypes: epidemiology, pathogenesis and diagnostic implications (Hedman)
  - Standardization update (Baylis)
  - Safety models in Europe (Bluemel)
  - TRIPS and RADAR studies in US (Yu, Kleinman)

- HAV and HEV
  - Virology, epidemiology, infectivity, pathogenesis (Purcell)
  - HEV in Japanese blood donors (Ikeda)
  - Approaches to safeguard blood and plasma products (Kriel)

- Infectivity and Risk of WP and chronic infection stages
  - Human & animal data; risk modeling (Kleinman, Yoshizawa, Anderson, Weusten)
  - Residual risk in S. Africa (HIV and HBV) and Egypt (HCV) (Reddy, El Ekiaby)
IPFA/PEI 16th Workshop on
“Surveillance and Screening of Blood Borne Pathogens”

In collaboration with the Belgian Scientific Institute of Public Health
In conjunction with the XXI meeting of the SoGAT on 28-29 May

26-27 May 2009
Brussels, Belgium
16th IPFA/PEI NAT Workshop (Brussels, 2009)

• HIV
  • Update on pathogenesis of HIV/AIDS (Barre-Sinoussi)
  • Early bottleneck & concept of “transmitted-founder” viruses (Shaw)
  • Implications of new insights on T/F viruses and EC for blood safety (Busch)

• PRT
  • Future contribution of PRT to blood safety (Klein)
  • PRT in context of serological combo-tests vs MP-NAT (Laperche)
  • Convincing the regulators (Heiden)
  • Clinical experience and cost-effectiveness of PRT (Osselaer, Van der Poel)

• Manufacturers updates
  • Abbott’s global surveillance and discovery initiatives (Brennan/Schochetman)
  • Roche’s multi-dye assays (Saldanha)
  • Novartis/Gen-Probe’s Ultrio-Plus & capacity to support ID-NAT (Lelie, Linnen)

• HBV screening in developing countries (Allain, Goubran, Permpikul, Galube)

• Emerging ID risks
  • Dengue, Leishmania, malaria (Margolis, Cardo, Bates)
  • Canadian Consensus Conference on Response to EIDs (Sher)
IPFA/PEI 17th Workshop on
“Surveillance and Screening of Blood Borne Pathogens”

In collaboration with the Institute of Immunology, Inc., Croatia

26-27 May 2010
The Regent Esplanade Zagreb Hotel, Croatia
• RBC parasites
  • Malaria
    • The challenge and potential responses (Chiodini)
    • Deferral & testing strategies for non-endemic countries (Kumar)
    • Donor screening vs treating pts in hyper-endemic countries (Owusu-Ofori)
  • Babesia: epidemiology; serology vs NAT screening (Leiby)

• Emerging Infections
  • XMRV & CFS (Dodd, Alter: “NIH confirmed detection of MLVs in CFS pts!”)
  • Dengue and Chikungunya (Lam)
  • WNV in Italy and Europe (Velati)
  • Q Fever in the Netherlands (Zaaijar)
  • Managing regional and seasonal EIDs – selective/targeted testing

• Updates
  • PRT vs screening: FDA perspective (Hewlett)
  • 10 years of NAT: Achievements and Challenges (Busch)
  • HBsAg variants and OBI (Allain)
  • vCJD: advances in screening (Coste)

• Plasma: HEV, developing countries, risk assessments (Matsubayashi, Baylis, Ayob, Over)
IPFA/PEI 18th Workshop on
“Surveillance and Screening of Blood Borne Pathogens”

In collaboration with the Irish Blood Transfusion Service

24-25 May 2011
Radisson Blu Royal Hotel, Dublin, Ireland
• XMRV
  • Discovery & controversial association with prostate CA & CFS (Silverman)
  • European view (Blomberg)
  • US XMRV Blood Safety Working Group studies (Busch)

• Emerging Pathogens
  • Impact of human activity on evolution of viruses (Hatzakis)
  • WHO view on EIDs (Padilla)
  • Endogenous Retroviruses – benign or malignant (Lower)

• European Directorate of Quality of Medicines (O’Riordan)
  • Surveys on collection, testing, safety (van der Poel, Janssen)

• Updates: HEV, vCJD, PRT trial design, HBV infectivity (Ijaz, Will, Heddle, Tanaka)

• Blood Selection and Epidemiology (Allain)
  • Evidence of value of donor selection and risk screening (Farrugia, de Kort)
  • Types of donors vs blood safety in developing countries (Mbanya)

• Risk Analysis and Screening Algorithms (Sher, Kleinman, Montag-Lessing)
  • Prospects and projections for the next 10 years! (Epstein)
IPFA/PEI 19th International Workshop on
“Surveillance and Screening of Blood Borne Pathogens”

In collaboration with the Hungarian National Blood Transfusion Service

23-24 May 2012
Budapest Marriott Hotel, Budapest, Hungary
19th IPFA/PEI NAT Workshop (Budapest, 2012)

• Infection Risk/Outcomes vs Recipient Immune Status
  • General overview from transplantation medicine (Neuberger)
  • Impact of immune status of transfusion recipients on TTIDs (Allain)
  • HEV outcomes relative to host immune status (Izopet)

• New Technologies for Discovery and Screening
  • Overview of “Next Generation” platforms (Timmerman)
  • Metagenomics for discovery of novel viruses (Delwart)
  • Ultra-deep sequencing for pathogen screening (Chiu)

• Updates
  • Protein folding diseases – expanding spectrum beyond CJD (Aguzi)
  • On-line European CDC system for estimation of risk (Oei)
  • International survey of HBV risk and screening efficacy (Lelie)
  • PCR for bacterial contamination (Schmidt)
  • Plasma products: safety and barriers (El Ekiaby, Dichtelmuller, Baylis)

• Donor Selection and Haemovigilence
  • Iron and plasma protein depletion in donors (Kleinman, Hellstern)

• Risk Assessments/Epidemiology: the Limits of Screening (Verweij, Zaalijer, Custer)
IPFA/PEI 20th International Workshop on
“Surveillance and Screening of Blood Borne Pathogens”

In collaboration with the Finnish Red Cross Blood Service

23–24 April 2013
Crowne Plaza Helsinki, Finland

20th Anniversary Event